机构地区:[1]天津医科大学第二医院核医学科,300211 [2]天津医科大学第二医院肿瘤科,300211
出 处:《国际放射医学核医学杂志》2019年第3期230-234,共5页International Journal of Radiation Medicine and Nuclear Medicine
基 金:天津市教委科研计划项目(自然科学)(2018KJ073).
摘 要:目的评估CT引导下植入^125I放射性粒子治疗早期(IA、IB期)非小细胞肺癌(NSCLC)后对患者肺功能的影响。方法选取2013年10月至2018年6月接受^125I放射性粒子植入治疗的早期NSCLC患者58例,根据治疗前的肺功能检测结果将患者分为合并慢性阻塞性肺疾病(COPD)组16例(男性10例、女性6例)和不合并COPD组42例(男性28例、女性14例),术后2~6个月检测肺功能指标,包括第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、肺一氧化碳弥散量(DLCO)变化的情况。组间比较采用t检验。结果覆盖90%靶体积时的剂量(D90)为(114.3±10.2)Gy,90%剂量覆盖的靶体积百分比(V90)为(92.3±7.2)%,术后验证匹配周边剂量(MPD)的中位值为112.8Gy。随访6个月,不合并COPD组与合并COPD组患者治疗前后的FVC%差异均无统计学意义(t=0.70、0.20,均P>0.05)。合并COPD组治疗前后的DLCO之间的差异无统计学意义(t=1.11,P=0.563),但不合并COPD组治疗前后的DLCO之间的差异有统计学意义(t=2.29,P=0.019)。治疗前后,合并COPD组和不合并COPD组肿瘤体积之间的差异均无统计学意义(t=1.82、1.26,均P>0.05),但合并COPD组和不合并COPD组在治疗前后肿瘤体积之间的差异均有统计学意义(t=5.78、9.96,均P<0.001)。根据术后质量验证MPD和D90大小分为2组(>110Gy组和≤110Gy组),合并COPD组和不合并COPD组的FEV1%之间、FVC%之间的差异均无统计学意义(t=0.54、0.37、0.21、0.22,均P>0.05)。结论^125I放射性粒子植入治疗早期NSCLC对患者FEV1%和FVC%无明显影响,但能够改善不合并COPD且肿瘤明显缩小患者的肺功能。Objective To evaluate pulmonary function and tumor volume before and after CT- guided radioactive ^125I seed implantation in inoperable patients with and without chronic obstructive pulmonary disease(COPD) in early-stage(IA, IB) lung cancer. Methods From October 2013 to June 2018, 58 patients with early non-small cell lung cancer were treated with ^125I radioactive seed implantation. Patients were divided according to the results of pre-treatment pulmonary function tests: 16 patients(10 males and 6 females) were included in the COPD groups and 42 patients(28 males and 14 females) were included in the No-COPD group. Changes in pulmonary function forced expiratory volume in one second, diffusing capacity of the lungs for carbon monoxide(DLCO), and forced vital capacity were detected within 2-6 months after operation. Statistical analysis was conducted via t test. Results The D90 was(114.3±10.2) Gy, the V90 was(92.3±7.2)%, and the matched peripheral dose was 112.8 Gy. The pretreatment and post treatment FEV% of the COPD and No-COPD groups were similar at a mean follow-up time of 6 months(t =0.70, 0.20, both P>0.05). The DLCO of the COPD group did not change after CT-guided radioactive ^125I seed implantation treatment(t=1.11, P=0.563);however, DLCO significantly increased in the No-COPD group(t=2.29, P=0.019). There was no significant difference in the tumor volume between the COPD group and the No-COPD group before and after treatment(t=1.82, 1.26, both P>0.05), but the difference between the COPD group and the tumor volume of the No-COPD group was statistically significant before and after the treatment(t=5.78, 9.96, both P<0.001). According to postoperative quality validation of MPD and D90, all the patients were divided into > 110 Gy group(34 cases) and ≤110 Gy group(24 cases), differences in the FEV1% and FVC% of the COPD and No-COPD groups after implantation were not statistically significant(t=0.54, 0.37, 0.21, 0.22, all P>0.05). Conclusion ^125I implantation therapy for inoperable non-small cell lung can
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...